Aeglea Biotherapeutics Inc. (NASDAQ:AGLE)’s share price reached a new 52-week low on Thursday . The company traded as low as $3.89 and last traded at $4.01, with a volume of 54,952 shares. The stock had previously closed at $4.56.

AGLE has been the subject of a number of research analyst reports. Needham & Company LLC initiated coverage on shares of Aeglea Biotherapeutics in a research report on Monday, May 9th. They set a “buy” rating and a $18.00 price objective for the company. Wells Fargo & Co. initiated coverage on shares of Aeglea Biotherapeutics in a research report on Monday, May 2nd. They set an “outperform” rating for the company. Finally, BMO Capital Markets initiated coverage on shares of Aeglea Biotherapeutics in a research report on Monday, May 2nd. They set an “outperform” rating and a $19.00 price objective for the company.

The firm’s market capitalization is $53.94 million. The company’s 50 day moving average price is $6.19 and its 200 day moving average price is $7.52.

Aeglea Biotherapeutics (NASDAQ:AGLE) last announced its earnings results on Friday, May 20th. The company reported ($7.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by $6.68. On average, equities analysts anticipate that Aeglea Biotherapeutics Inc. will post ($2.35) EPS for the current fiscal year.

In other Aeglea Biotherapeutics news, Director Anthony Quinn bought 10,000 shares of the stock in a transaction dated Tuesday, April 12th. The shares were acquired at an average cost of $10.00 per share, for a total transaction of $100,000.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at approximately $100,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Bioventures Ltd Novartis bought 300,000 shares of the stock in a transaction dated Tuesday, April 12th. The shares were acquired at an average price of $10.00 per share, for a total transaction of $3,000,000.00. The disclosure for this purchase can be found here.

Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.